article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

2022 was a banner year for genomics. In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA.

Genome 122
article thumbnail

Evaluating methods targeting Protein-Protein Interactions

pharmaphorum

Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. PPIs are an integral part of the physiology of living organisms, as complexes which control biological pathways mediated by proteins. These regions are critical for optimal interactions between proteins.

Protein 125
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Innovation in immuno-oncology: Leading companies in oncolytic viral proteins

Pharmaceutical Technology

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Oncolytic viral proteins. Sillajen and Advaxis are the other key patent filers of oncolytic viral proteins.

Protein 130
article thumbnail

Eurofins Genomics and Olink partner to advance proteomics research

Drug Discovery World

Eurofins Genomics has adopted Olink technology to advance proteomics research and accelerate its precision medicine programmes. Olink Explore HT is the company's latest solution for high-throughput proteomics, allowing scientists to accurately measure over 5,300 proteins [.] To read this content in full, you need to login.

Genome 59
article thumbnail

X-Chem and Structural Genomics Consortium partner to ‘unlock potential’ of human proteome

BioPharma Reporter

X-Chem, a company focused on drug discovery services, and the Structural Genomics Consortium (SGC), a public-private partnership accelerating drug discovery through open science, have partnered to create new chemical tools to study human proteins.

Genome 64
article thumbnail

Junk DNA: How the dark genome is changing RNA therapies

Drug Discovery World

Decoding ‘junk DNA’ The Human Genome Project and subsequent studies discovered that most of our DNA (approximately 98%) does not actually code for proteins, with humans having approximately 20,000 tox 25,000 protein-coding genes.

RNA 52
article thumbnail

Researchers discover mechanism linking mutations in the ‘dark matter’ of the genome to cancer

Scienmag

For many years, the human genome was viewed as a book of life in which sections of great eloquence and economy of expression were interspersed with vast stretches of gibberish.

Genome 77